NAMPT and non-small cell lung carcinoma: Consistent with our findings, a recent study suggests that NAD depletion with the NAMPT inhibitor GNE-618, developed by Genentech, led to decreased nucleotide, lipid, and amino acid synthesis, which may have contributed to the cell cycle effects arising from NAD depletion in non-small-cell lung carcinoma cell lines [46].